CUE Nasdaq

Cue Biopharma, Inc.

CUE | $1.42 -5.33% -4.9% 320K

(0.0% 1d) (-22.8% 1m) (-64.5% 1y) (0.0% 2d) (-5.3% 3d) (-9.0% 7d) (97.89% volume)
Earnings Calendar: 2024-03-12
Market Cap: $ 69,073,509
http://www.cuebiopharma.com
Sec Filling | Patents | 47 employees

(US) Cue Biopharma, Inc. is a biopharmaceutical company, which engages in the development of a novel and proprietary class of biologic drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its pipeline includes Immuno-oncology, CUE-100 framework, CUE-200 framework, and autoimmune disease. The company was founded on December 31, 2014 and is headquartered in Cambridge, MA.

cancer autoimmunity glass

add to watch list Paper trade email alert is off

Press-releases

Cue Biopharma to Present at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
Published: 2024-04-24 (Crawled : 14:00) - globenewswire.com
CUE | $1.42 -5.33% -4.9% 320K

Health Technology

| -5.33% | O: 2.0% H: 3.27% C: -7.19%
cue biopharma meeting

Cue Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results and Updated Business Highlights
Published: 2024-04-08 (Crawled : 20:00) - globenewswire.com
CUE | $1.42 -5.33% -4.9% 320K

Health Technology

| -30.39% | O: -4.9% H: 1.03% C: -2.06%
business year cue financial results

Cue Biopharma to Host Business Update Call and Webcast
Published: 2024-04-02 (Crawled : 12:00) - globenewswire.com
CUE | $1.42 -5.33% -4.9% 320K

Health Technology

| -23.04% | O: 1.9% H: 3.72% C: -3.19%
business cue update

Cue Biopharma’s Lead Clinical Asset, CUE-101, to be Featured at the 2024 Multi-disciplinary Head and Neck Cancers Symposium
Published: 2024-02-29 (Crawled : 15:00) - globenewswire.com
CUE | $1.42 -5.33% -4.9% 320K

Health Technology

| -33.02% | O: 0.47% H: 1.41% C: -2.58%
cue-101 symposium cue

Cue Biopharma to Present Corporate Update at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
Published: 2024-02-06 (Crawled : 13:00) - globenewswire.com
CUE | $1.42 -5.33% -4.9% 320K

Health Technology

| -40.34% | O: -1.68% H: 8.87% C: 7.26%
conference life cue update biopharma sciences

Cue Biopharma to Present at the JMP Securities Hematology and Oncology Summit
Published: 2023-11-22 (Crawled : 13:00) - globenewswire.com
CUE | $1.42 -5.33% -4.9% 320K

Health Technology

| -40.34% | O: 0.42% H: 1.67% C: 0.0%
cue biopharma

Cue Biopharma to Present at Three Upcoming Investor Healthcare Conferences in November
Published: 2023-11-07 (Crawled : 13:00) - globenewswire.com
CUE | $1.42 -5.33% -4.9% 320K

Health Technology

| -44.31% | O: 0.0% H: 3.79% C: 0.0%
cue biopharma

Cue Biopharma Presents New Positive Data from Phase 1 Trials of CUE-101 in Head and Neck Cancer and CUE-102 in Wilms’ Tumor 1 Positive Cancers at SITC 2023
Published: 2023-11-03 (Crawled : 16:00) - globenewswire.com
CUE | $1.42 -5.33% -4.9% 320K

Health Technology

| -36.04% | O: 1.35% H: 16.44% C: 8.89%
cue-101 positive cue cancer biopharma tumor cue-102 trials

Cue Biopharma to Host Business Update Call and Webcast
Published: 2023-11-02 (Crawled : 12:00) - globenewswire.com
CUE | $1.42 -5.33% -4.9% 320K

Health Technology

| -29.7% | O: 1.49% H: 8.78% C: 8.29%
business cue update

Cue Biopharma Announces Upcoming Scientific Presentations at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting
Published: 2023-09-27 (Crawled : 13:00) - globenewswire.com
CUE | $1.42 -5.33% -4.9% 320K

Health Technology

| -39.83% | O: 0.42% H: 8.02% C: 2.95%
cue biopharma immunotherapy meeting

See all

Last 15 days Sec forms

File Id	Form	Published Date	Transaction Date	Direction	Code	Amount Transacted	Owned Amount
0001209191-23-046000	4	2023-08-16	2023-08-14	Buy	P	3000	134578
0001209191-23-043278	4	2023-07-25	2023-07-21	Buy	A	82500	82500
0001209191-23-043277	4	2023-07-25	2023-07-21	Buy	A	113000	113000
0001209191-23-043276	4	2023-07-25	2023-07-21	Buy	A	450000	450000